These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1166 related articles for article (PubMed ID: 19666851)

  • 21. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.
    Behl AS; Goddard KA; Flottemesch TJ; Veenstra D; Meenan RT; Lin JS; Maciosek MV
    J Natl Cancer Inst; 2012 Dec; 104(23):1785-95. PubMed ID: 23197490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
    Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY
    Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
    Karapetis CS; Khambata-Ford S; Jonker DJ; O'Callaghan CJ; Tu D; Tebbutt NC; Simes RJ; Chalchal H; Shapiro JD; Robitaille S; Price TJ; Shepherd L; Au HJ; Langer C; Moore MJ; Zalcberg JR
    N Engl J Med; 2008 Oct; 359(17):1757-65. PubMed ID: 18946061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KRAS early testing: consensus initiative and cost-effectiveness evaluation for metastatic colorectal patients in an Italian setting.
    Barone C; Pinto C; Normanno N; Capussotti L; Cognetti F; Falcone A; Mantovani L
    PLoS One; 2014; 9(1):e85897. PubMed ID: 24465771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment.
    Starling N; Tilden D; White J; Cunningham D
    Br J Cancer; 2007 Jan; 96(2):206-12. PubMed ID: 17242694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England.
    Tikhonova IA; Huxley N; Snowsill T; Crathorne L; Varley-Campbell J; Napier M; Hoyle M
    Pharmacoeconomics; 2018 Jul; 36(7):837-851. PubMed ID: 29498000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada.
    Hedden L; Kennecke H; Villa D; Johnston K; Speers C; Kovacic L; Renouf DJ; Peacock S
    Eur J Cancer; 2012 Sep; 48(13):1969-76. PubMed ID: 22325838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
    Shiroiwa T; Fukuda T; Tsutani K
    Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
    Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
    JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States.
    Shankaran V; Ortendahl JD; Purdum AG; Bolinder B; Anene AM; Sun GH; Bentley TGK
    Am J Clin Oncol; 2018 Jan; 41(1):65-72. PubMed ID: 26398184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.
    Tabernero J; Cervantes A; Rivera F; Martinelli E; Rojo F; von Heydebreck A; Macarulla T; Rodriguez-Braun E; Eugenia Vega-Villegas M; Senger S; Ramos FJ; Roselló S; Celik I; Stroh C; Baselga J; Ciardiello F
    J Clin Oncol; 2010 Mar; 28(7):1181-9. PubMed ID: 20100964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan--a Belgian analysis.
    Annemans L; Van Cutsem E; Humblet Y; Van Laethem JL; Bleiberg H
    Acta Clin Belg; 2007; 62(6):419-25. PubMed ID: 18351186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
    Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
    J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
    Rivera F; Valladares M; Gea S; López-Martínez N
    J Med Econ; 2017 Jun; 20(6):574-584. PubMed ID: 28107090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
    Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
    Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.
    Price TJ; Peeters M; Kim TW; Li J; Cascinu S; Ruff P; Suresh AS; Thomas A; Tjulandin S; Zhang K; Murugappan S; Sidhu R
    Lancet Oncol; 2014 May; 15(6):569-79. PubMed ID: 24739896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.
    Jacobs B; De Roock W; Piessevaux H; Van Oirbeek R; Biesmans B; De Schutter J; Fieuws S; Vandesompele J; Peeters M; Van Laethem JL; Humblet Y; Pénault-Llorca F; De Hertogh G; Laurent-Puig P; Van Cutsem E; Tejpar S
    J Clin Oncol; 2009 Oct; 27(30):5068-74. PubMed ID: 19738126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 59.